ALLAKOS INC. - COMMON STOCK

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 Mar 2024 15:02:00 By Nasdaq GlobeNewswire

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

26 Feb 2024 06:02:00 By Nasdaq GlobeNewswire

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

12 Feb 2024 06:02:00 By Nasdaq GlobeNewswire

Allakos Announces a Restructuring to Focus on Development of AK006

16 Jan 2024 06:02:00 By Nasdaq GlobeNewswire

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

16 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

13 Nov 2023 15:02:00 By Nasdaq GlobeNewswire

Allakos Appoints Neil Graham to its Board of Directors

30 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

09 Aug 2023 15:02:00 By Nasdaq GlobeNewswire

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

02 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

12 Jun 2023 06:02:00 By Nasdaq GlobeNewswire

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

05 Jun 2023 06:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

09 May 2023 15:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

06 Mar 2023 15:02:00 By Nasdaq GlobeNewswire

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

29 Nov 2022 06:02:00 By Nasdaq GlobeNewswire

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

10 Nov 2022 08:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

07 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

19 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

12 Sep 2022 06:02:00 By Nasdaq GlobeNewswire

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

09 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

04 Aug 2022 15:04:00 By Nasdaq GlobeNewswire